secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001493152-26-008326
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 3.03, 5.07, 5.03, 5.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus stockholders approve proposals enabling David Lazar to obtain 96.4% control; board changes
--------------------------------------------------------------------------------

- Lazar purchased $6.0M of preferred stock; upon conversion, 111M common shares issuable, representing ~96.4% of fully diluted outstanding.
- Authorized common stock increased from 200M to 1B shares; reverse stock split authorized at ratio 1:2 to 1:199.
- Jerome Jabbour and Matthew McMurdo elected as directors; Mark Gilbert and Michael Newman resigned immediately after meeting.
- Stockholders approved stockholder action by written consent and issuance of common stock upon conversion of preferred stock.
- Lazar's nominees now constitute majority of nine-member board; company plans to pursue strategic transaction with target company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/0001493152-26-008326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer